Article Text

PDF

Inflammatory bowel disease III
PWE-254 Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease
  1. J-F Colombel1,
  2. P J Rutgeerts2,
  3. W J Sandborn3,
  4. W Reinisch4,
  5. E V Loftus Jr5,
  6. J Tang6,
  7. P F Pollack7,
  8. M Yang7,
  9. S P Patel8,
  10. B Huang7,
  11. J Chao7,
  12. P M Mulani7
  1. 1Centre Hospitalier Universitaire de Lille, Lille, France
  2. 2University Hospital of Gasthuisberg, Leuven, Belgium
  3. 3University of California, San Diego, La Jolla, California, USA
  4. 4Medical University of Vienna, Vienna, Austria
  5. 5Mayo Clinic, Rochester, Minnesota, USA
  6. 6Analysis Group Inc, Boston, Massachusetts, USA
  7. 7Abbott Laboratories, Abbott Park, Illinois, USA
  8. 8Abbott Laboratories Ltd, Maidenhead, Berkshire, UK

Abstract

Introduction Two induction regimens of adalimumab are used in Crohn's disease (CD): 160/80 mg or 80/40 mg at Weeks 0/2. We compared long-term efficacy for patients who received 160/80 mg vs 80/40 mg as induction therapy followed by eow maintenance therapy.

Methods Data were from two randomised, double-blinded, placebo-controlled efficacy and safety trials in moderate to severe CD. EXTEND, a 52-week study in patients with mucosal ulceration, used the 160-/80-mg induction regimen. CHARM, a 56-week study for maintenance of clinical remission, used the 80-/40-mg induction regimen. All patients who started with induction dose and were randomised to eow plus dropouts prior to Week-4 randomisation were included. Missing Crohn's Disease Activity Index (CDAI) scores were imputed with both non-responder imputation (NRI) and last observation carried forward (LOCF). Remission (CDAI <150) and hospitalisation were compared between induction regimens. To incorporate the correlation between visits for a patient, a logistic regression with the patient-level random intercept using all the time points after Week 4 was constructed to compare likelihood of remission, controlling for baseline CDAI, fistula, prior use of an anti–tumour necrosis factor therapy, concomitant medications, CD duration, and other factors.

Results 70 patients in the 160-/80-mg group were compared with 336 patients in the 80-/40-mg group. Baseline characteristics were similar except for greater rates of rectal/anal CD in the 160-/80-mg group and greater use of concomitant steroids in the 80-/40-mg group. Compared with the 80-/40-mg group, the 160-/80-mg group had a greater percentage of time in remission from Week 0–52 (36% vs 25%; p<0.05, NRI), significantly fewer hospitalisations per patient (0.09 vs 0.23; p<0.05), and significantly fewer CD-related hospitalisations (0.07 vs 0.18; p<0.05). Patients in the 160-/80-mg group were significantly more likely to be in remission during Weeks 4 to 52 than were patients in the 80-/40-mg group after adjusting for baseline characteristics (adjusted OR 4.8; p<0.001). LOCF results for remission analysis were consistently similar. The 160-/80-mg regimen did not appear to lead to a higher rate of AEs.

Conclusion The 160-/80-mg induction regimen of adalimumab was associated with a greater likelihood of remission, more time in remission, and fewer hospitalisations during eow maintenance therapy compared with the 80-/40-mg regimen.

Competing interests J-F Colombel Consultant for: Abbott, Speaker bureau with: Abbott, P Rutgeerts Grant/Research Support from: Abbott, Consultant for: Abbott, Speaker bureau with: Abbott, Conflict with: Abbott, W Sandborn Grant/Research Support from: Abbott, Consultant for: Abbott (fees paid to Mayo), W Reinisch Consultant for: Abbott, Conflict with: Abbott, E Loftus Jr Grant/Research Support from: Abbott, Consultant for: Abbott, J Tang Consultant for: Abbott, Employee of: Analysis Group, P Pollack Shareholder with: Abbott, Employee of: Abbott, M Yang Shareholder with: Abbott, Employee of: Abbott, S Patel Shareholder with: Abbott, Employee of: Abbott, B Huang Shareholder with: Abbott, Employee of: Abbott, J Chao Shareholder with: Abbott, Employee of: Abbott, P Mulani Shareholder with: Abbott, Employee of: Abbott.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.